Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

Gratzke C.J.; Egils Vjaters; Fizazi K.; C.J. GratzkeK. FizaziNeal Shore[...]F. Verholen; Verholen; Shore N.D.; Smith M.R.; C.J. GratzkeK. FizaziNeal Shore[...]F.; Feyerabend S.; Grabbert M.; Carles J.; Lebret T.

doi:10.1016/j.annonc.2021.08.1143

Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

Gratzke C.J.
, Egils Vjaters
, Fizazi K.
, C.J. GratzkeK. FizaziNeal Shore[...]F. Verholen
, Verholen
, Shore N.D.
, Smith M.R.
, C.J. GratzkeK. FizaziNeal Shore[...]F.
, Feyerabend S.
, Grabbert M.
, Carles J.
, Lebret T.

Ne LU

Zinātniskās darbības rezultāts: Devums žurnālam › Konferences tēzes (žurnālā) › koleģiāli recenzēts

Oriģinālvaloda	Angļu
Žurnāls	Annals of Oncology
Sējums	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.1143
Publikācijas statuss	Publicēts - 2021

OECD Zinātnes nozare

3. Medicīnas un veselības zinātnes

Piekļuve Dokumentiem

10.1016/j.annonc.2021.08.1143

Citi faili un saites

https://www.annalsofoncology.org/article/S0923-7534(21)03372-X/fulltext#relatedArticles

Citēt šo

C.J., G., Vjaters, E., K., F., GratzkeK. FizaziNeal Shore[...]F. Verholen, C. J., Verholen, N.D., S., M.R., S., C.J. GratzkeK. FizaziNeal Shore[...]F., S., F., M., G., J., C., & T., L. (2021). Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial. Annals of Oncology, 32. https://doi.org/10.1016/j.annonc.2021.08.1143

@article{24589166680f4110b7d55dedfd22494e,

title = "Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial",

author = "Gratzke C.J. and Egils Vjaters and Fizazi K. and \{GratzkeK. FizaziNeal Shore[...]F. Verholen\}, C.J. and Verholen and Shore N.D. and Smith M.R. and \{C.J. GratzkeK. FizaziNeal Shore[...]F.\} and Feyerabend S. and Grabbert M. and Carles J. and Lebret T.",

year = "2021",

doi = "10.1016/j.annonc.2021.08.1143",

language = "English",

volume = "32",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

C.J., G, Vjaters, E, K., F, GratzkeK. FizaziNeal Shore[...]F. Verholen, CJ, Verholen, N.D., S, M.R., S, C.J. GratzkeK. FizaziNeal Shore[...]F., S., F, M., G, J., C & T., L 2021, 'Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial', Annals of Oncology, sēj. 32. https://doi.org/10.1016/j.annonc.2021.08.1143

TY - JOUR

T1 - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

AU - C.J., Gratzke

AU - Vjaters, Egils

AU - K., Fizazi

AU - GratzkeK. FizaziNeal Shore[...]F. Verholen, C.J.

AU - Verholen, null

AU - N.D., Shore

AU - M.R., Smith

AU - C.J. GratzkeK. FizaziNeal Shore[...]F., null

AU - S., Feyerabend

AU - M., Grabbert

AU - J., Carles

AU - T., Lebret

PY - 2021

Y1 - 2021

UR - https://www.annalsofoncology.org/article/S0923-7534(21)03372-X/fulltext#relatedArticles

U2 - 10.1016/j.annonc.2021.08.1143

DO - 10.1016/j.annonc.2021.08.1143

M3 - Meeting abstract

SN - 0923-7534

VL - 32

JO - Annals of Oncology

JF - Annals of Oncology

ER -